Invention Grant
- Patent Title: Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
-
Application No.: US17232015Application Date: 2021-04-15
-
Publication No.: US11999738B2Publication Date: 2024-06-04
- Inventor: Laurent Gomez , William Francois Vernier
- Applicant: DART NEUROSCIENCE, LLC
- Applicant Address: US TX Dallas
- Assignee: Dart NeuroScience, LLC
- Current Assignee: Dart NeuroScience, LLC
- Current Assignee Address: US TX Dallas
- Agency: Knobbe, Martens, Olson & Bear LLP
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; A61P25/00 ; A61P25/22 ; A61P25/24 ; A61P25/28

Abstract:
A chemical entity of Formula (I):
wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.
wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.
Public/Granted literature
- US20210340145A1 SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS Public/Granted day:2021-11-04
Information query